<DOC>
	<DOCNO>NCT01007292</DOCNO>
	<brief_summary>The purpose study evaluate response rate , survival , safety tolerability YM155 give combination rituximab subject Non-Hodgkin 's Lymphoma .</brief_summary>
	<brief_title>A Study YM155 Plus Rituximab Subjects With Non-Hodgkin 's Lymphoma Who Have Received Prior Treatment</brief_title>
	<detailed_description>This outpatient study . All subject enrol study receive YM155 rituximab give 14 day cycle . Each subject assess end cycle determine may continue next cycle . Each subject eligible continue receive combination regimen study one discontinuation criterion meet . If subject discontinues treatment without progressive disease ( PD ) subject complete follow-up visit every 12 week 1 year initiate another systemic anti-lymphoma treatment , exhibit PD , death . Each subject contact study site every 12 week survival follow End Treatment Visit . The contact continue death 1 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Any stage , histologically confirm CD20positive primary transform diffuse large B cell lymphoma ( DLBCL ) grade 3 follicular lymphoma ( FL ) Ineligible previously receive autologous stem cell transplant ( ASCT ) Relapsed follow receipt last dose systemic chemotherapy ASCT At least one prior chemotherapy regimen . Prior chemotherapy regimen must contain anthracycline ( unless contraindicate ) If subject female , must nonpregnant nonlactating Baseline Visit . All sexually active male female childbearing potential must agree use adequate method contraception throughout study period Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; /= 1 Use standard/experimental antilymphoma drug therapy within 21 day Baseline Visit Use systemic steroid within 5 day Baseline Visit ( except purpose premedication prior study regimen treatment ) Prior allogeneic stem cell transplant ( SCT ) The subject previously treat YM155 The subject know human immunodeficiency virus ( HIV ) , hepatitis B surface antigen , hepatitis C antibody The subject receive investigational therapy procedure within 21 day prior first study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>relapse</keyword>
	<keyword>CD20-Positive</keyword>
	<keyword>YM155</keyword>
</DOC>